lower gastrointestinal diseases
Conditions
Interventions
Group A: ingestion Patients group A ingest PN-2 three times per a day. They are required to consecutive by ingest PN-2 for 7 days before surgery. In the same way, a consecutive intake of 7 days is r
Sponsors
Osaka University Graduate School of Medicine Department of Complementary and Alternative Medicine
Osaka General Medical Center Department of Digestive Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients diagnosed with lower gastrointestinal diseases. 2) Patients expected over 3 month-survival from the first day of this study. 3) Patients who can orally ingestion. 4) Patients who are obtained with the prior written consent.
Exclusion criteria
Exclusion criteria: 1) Patients with the following diseases. (cirrhosis, chronic renal failure, diabetes with insulin therapy and so on) 2) Patients with steroid treatment 3) Patients with a disorder of amino acid metabolism. 4) Patients with food allergy. 5) Patients less than 20 years old. 6) Patients have experience of chemotherapy. 7) Patients judged to be inappropriate for this study from the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We evaluate the safety of 'PN-2' by checking hematology,blood biochemistry, urine test and the adverse events by following CTCAE v4.0 index. Evaluations as above are carried out three times,i.e.;seven days before surgery, just before surgery and about 10 days after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| We evaluate the efficiency of 'PN-2' by checking the following indices: aminogram, immunological tests, wound hearing, complications and length of hospitalization. Evaluations as above are carried out three times,i.e.; seven days before surgery, just before surgery and about 10 days after surgery. | — |
Countries
Japan
Contacts
Public ContactAsuka Yasueda
Osaka University Graduate School of Medicine Department of Complementary and Alternative Medicine
Outcome results
None listed